Lower urinary tract dysfunction in MS: management in the community

Author(s): Panicker J, Haslam C

Abstract

Lower urinary tract dysfunction in multiple sclerosis is common and is highly amenable to treatment. Individuals may have bladder storage and/or voiding dysfunction. The risk of progression to renal failure is low and hence lower urinary tract dysfunction should be considered medically manageable in most individuals. Evaluation begins with history taking and is supplemented by using a bladder diary. Ultrasonography is used to assess the degree of incomplete bladder emptying, and for assessing upper urinary tract damage. Incomplete bladder emptying is most often managed by clean intermittent self-catheterization and should be initiated if post-void residual urine is greater than 100 mls. Storage symptoms are most often managed using antimuscarinic medications. Other options include desmopressin or detrusor muscle injection of botulinum toxin type A. There are specific situations where specialist urology services should be involved.

Similar Articles

A UK consensus on the management of the bladder in multiple sclerosis

Author(s): Fowler CJ, Panicker JN, Drake M, Harris, Harrison SCW, et al.

Disparities in the management of multiple sclerosis-related bladder symptoms

Author(s): MarrieRA, Cutter G, Tyry T, Vollmer T, Campagnolo D

The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines

Author(s): de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B; GENULF

Urinary complications and risk factors in symptomatic multiple sclerosis patients

Author(s): Castel-Lacanal E, Gamé X, Clanet M, Gasq D, De Boissezon X, et al.

The neural control of micturition

Author(s): Fowler CJ, Griffiths D, de Groat WC

Botulinum toxin treatment for bladder dysfunction

Author(s): Santos-Silva A, da Silva CM, Cruz F

Renal deterioration in multiple sclerosis patients with neurovesical dysfunction

Author(s): Fletcher SG, Dillon BE, Gilchrist AS, Haverkorn RM, Yan J, et al.

First-line urological evaluation in multiple sclerosis: validation of a specific decision-making algorithm

Author(s): Amarenco G, Chartier-Kastler E, Denys P, Jean JL, de Seze M et al.

Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis

Author(s): Koldewijn EL, Hommes OR, Lemmens WA, Debruyne FM, van Kerrebroeck PE

Role of cannabinoids in multiple sclerosis

Author(s): Zajicek JP, Apostu VI

Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis

Author(s): Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

Author(s): Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, et al.

The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review

Author(s): Tubaro A, Puccini F, De Nunzio C, Digesu GA, Elneil S, et al.

Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder

Author(s): Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, et al.

Botulinum toxin therapy for neurogenic detrusor overactivity

Author(s): Smaldone MC1, Ristau BT, Leng WW

Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis

Author(s): Kessler TM, La Framboise D, Trelle S, Fowler CJ, Kiss G, et al.

Clinical outcomes of sacral neuromodulation in patients with neurologic conditions

Author(s): Peters KM, Kandagatla P, Killinger KA, Wolfert C, Boura JA

Impact of intermittent catheterization on the quality of life of multiple sclerosis patients

Author(s): Castel-Lacanal E, Gamé X, De Boissezon X, Guillotreau J, Braley-Berthoumieux E, et al.